Last reviewed 2026-04-20 · How we verify

ALECTINIB HYDROCHLORIDE

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Edema
• Constipation
• Nausea
• Diarrhea
• Vomiting
• Pneumonia
• Renal impairment
• Hyperbilirubinemia
• Increased AST
• Increased ALT
• Increased alkaline phosphatase

Key clinical trials

• Pharmacogenomics ANDA 221517 SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms (PHASE2, PHASE3)
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (PHASE2)
• KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
• A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PHASE2)
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (PHASE2)
• The Drug Rediscovery Protocol (DRUP Trial) (PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ALECTINIB HYDROCHLORIDE CI brief — competitive landscape report
• ALECTINIB HYDROCHLORIDE updates RSS · CI watch RSS